Research Topics
| Greetje J TackSummaryAffiliation: VU University Medical Center Country: The Netherlands Publications
|
Detail Information
Publications
Serum parameters in the spectrum of coeliac disease: beyond standard antibody testing--a cohort studyGreetje J Tack
Department of Gastroenterology and Hepatology, VU University Medical Centre, PO Box 7057, Amsterdam 1007 MB, The Netherlands
BMC Gastroenterol 12:159. 2012..Invasive techniques are still required to distinguish between uncomplicated and complicated forms of CD...
Tioguanine in the treatment of refractory coeliac disease--a single centre experienceG J Tack
Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands
Aliment Pharmacol Ther 36:274-81. 2012..Besides corticosteroids, azathioprine has been advocated for the treatment of refractory coeliac disease type I. However, tioguanine (TG) might be better tolerated and more efficacious owing to a simpler metabolism towards bioactivation...
Origin and immunophenotype of aberrant IEL in RCDII patientsGreetje J Tack
Gastroenterology and Hepatology, VU University Medical Center, The Netherlands
Mol Immunol 50:262-70. 2012..The aim of this study was to gain further insight in the origin and characteristics of aberrant IELs by analysing T-cell receptor (TCR) rearrangements, and by immunophenotypic analysis of aberrant IELs...
The spectrum of celiac disease: epidemiology, clinical aspects and treatmentGreetje J Tack
Department of Gastroenterology and Hepatology, VU University Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
Nat Rev Gastroenterol Hepatol 7:204-13. 2010..This complication is referred to as refractory celiac disease, and imposes a serious risk of developing a virtually lethal enteropathy-associated T-cell lymphoma...
Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapyG J Tack
Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
Bone Marrow Transplant 46:840-6. 2011..5 months. EATL was observed in one transplanted patient, only after 4 years of follow-up. Auto-SCT after conditioning with high-dose chemotherapy in RCD II patients unresponsive to cladribine therapy is feasible and seems promising...
Evaluation of Cladribine treatment in refractory celiac disease type IIGreetje J Tack
Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, The Netherlands
World J Gastroenterol 17:506-13. 2011..To evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) II...
